

Dear Colleagues,

The 2021 NCI Alliance for Nanotechnology in Cancer PI meeting will be held October 20-21, remotely. We would like to invite you to join us at the meeting.

The meeting website <https://events.cancer.gov/dctd/nanopi/registration> contains the overview, agenda and registration pages. We would appreciate that you register by *Saturday, October 16, 2021*.

Annual Meeting Background

The convergence of nanotechnology and cancer research carries great promise towards addressing several fundamental problems of cancer biology and clinical oncology. In September 2005, the National Cancer Institute (NCI) launched the NCI Alliance for Nanotechnology in Cancer (<https://www.cancer.gov/sites/nano>) to support the development of nanomaterials and nanotechnology-enabled devices for clinical applications in cancer diagnosis and treatment. It was the first program to support large-scale cooperative research in this area of medicine. The past sixteen years of the program's operation have been rich in significant scientific advances, high impact papers, patent disclosures, and new companies focused on the commercialization of these technologies.

2021 Focus

This year's Investigators' Meeting includes five themed sessions to reflect on priorities and strategies for the future of the field: 1) Nanodiagnostics; 2) Nanotechnology for COVID-19 applications; 3) Strategy directions for cancer nanotechnology; 4) Targeted Drug Delivery and Image-Guided Nanotherapy, and 5) Immunotherapy.

Contacts for Questions

If you have additional questions, please contact Dr. Carolina Salvador Morales (carolina.salvadormorales@nih.gov).

Thank you very much for your cooperation and we look forward to seeing you at the meeting.

With kind regards,

Piotr Grodzinski, Ph.D.
Director, Office of Cancer Nanotechnology Research
National Cancer Institute
grodzinp@mail.nih.gov